Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RPS20_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RPS20_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RPS20_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RPS20_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RPS20_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RPS20_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RPS20_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RPS20_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RPS20_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RPS20_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RPS20_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RPS20_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RPS20_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:19033209 | Breast | Precancer | regulation of protein modification by small protein conjugation or removal | 38/1080 | 242/18723 | 1.71e-08 | 1.17e-06 | 38 |
GO:19033219 | Breast | Precancer | negative regulation of protein modification by small protein conjugation or removal | 21/1080 | 95/18723 | 8.09e-08 | 4.61e-06 | 21 |
GO:00313969 | Breast | Precancer | regulation of protein ubiquitination | 33/1080 | 210/18723 | 1.45e-07 | 7.82e-06 | 33 |
GO:00313979 | Breast | Precancer | negative regulation of protein ubiquitination | 19/1080 | 83/18723 | 1.85e-07 | 9.54e-06 | 19 |
GO:19017989 | Breast | Precancer | positive regulation of signal transduction by p53 class mediator | 10/1080 | 25/18723 | 5.77e-07 | 2.49e-05 | 10 |
GO:19017969 | Breast | Precancer | regulation of signal transduction by p53 class mediator | 19/1080 | 93/18723 | 1.20e-06 | 4.60e-05 | 19 |
GO:00723319 | Breast | Precancer | signal transduction by p53 class mediator | 26/1080 | 163/18723 | 2.23e-06 | 7.76e-05 | 26 |
GO:19046679 | Breast | Precancer | negative regulation of ubiquitin protein ligase activity | 6/1080 | 12/18723 | 2.48e-05 | 5.71e-04 | 6 |
GO:00514449 | Breast | Precancer | negative regulation of ubiquitin-protein transferase activity | 7/1080 | 19/18723 | 5.68e-05 | 1.17e-03 | 7 |
GO:19046668 | Breast | Precancer | regulation of ubiquitin protein ligase activity | 7/1080 | 23/18723 | 2.26e-04 | 3.42e-03 | 7 |
GO:00514386 | Breast | Precancer | regulation of ubiquitin-protein transferase activity | 10/1080 | 53/18723 | 7.88e-04 | 9.29e-03 | 10 |
GO:00513489 | Breast | Precancer | negative regulation of transferase activity | 27/1080 | 268/18723 | 3.49e-03 | 2.90e-02 | 27 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:190332014 | Breast | IDC | regulation of protein modification by small protein conjugation or removal | 43/1434 | 242/18723 | 1.71e-07 | 9.16e-06 | 43 |
GO:003139614 | Breast | IDC | regulation of protein ubiquitination | 37/1434 | 210/18723 | 1.50e-06 | 6.36e-05 | 37 |
GO:190332114 | Breast | IDC | negative regulation of protein modification by small protein conjugation or removal | 22/1434 | 95/18723 | 2.16e-06 | 8.69e-05 | 22 |
GO:007233114 | Breast | IDC | signal transduction by p53 class mediator | 30/1434 | 163/18723 | 5.82e-06 | 1.89e-04 | 30 |
GO:190179814 | Breast | IDC | positive regulation of signal transduction by p53 class mediator | 10/1434 | 25/18723 | 7.56e-06 | 2.27e-04 | 10 |
GO:003139714 | Breast | IDC | negative regulation of protein ubiquitination | 19/1434 | 83/18723 | 1.25e-05 | 3.29e-04 | 19 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517164 | Oral cavity | NEOLP | Coronavirus disease - COVID-19 | 112/1112 | 232/8465 | 8.85e-40 | 2.82e-37 | 1.77e-37 | 112 |
hsa0301064 | Oral cavity | NEOLP | Ribosome | 81/1112 | 167/8465 | 4.35e-29 | 6.91e-27 | 4.35e-27 | 81 |
hsa0517174 | Oral cavity | NEOLP | Coronavirus disease - COVID-19 | 112/1112 | 232/8465 | 8.85e-40 | 2.82e-37 | 1.77e-37 | 112 |
hsa0301074 | Oral cavity | NEOLP | Ribosome | 81/1112 | 167/8465 | 4.35e-29 | 6.91e-27 | 4.35e-27 | 81 |
hsa0301028 | Prostate | BPH | Ribosome | 104/1718 | 167/8465 | 8.04e-33 | 1.33e-30 | 8.21e-31 | 104 |
hsa0517128 | Prostate | BPH | Coronavirus disease - COVID-19 | 115/1718 | 232/8465 | 5.65e-24 | 2.07e-22 | 1.28e-22 | 115 |
hsa03010113 | Prostate | BPH | Ribosome | 104/1718 | 167/8465 | 8.04e-33 | 1.33e-30 | 8.21e-31 | 104 |
hsa05171113 | Prostate | BPH | Coronavirus disease - COVID-19 | 115/1718 | 232/8465 | 5.65e-24 | 2.07e-22 | 1.28e-22 | 115 |
hsa0301029 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
hsa0517129 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
hsa0301037 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
hsa0517137 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
hsa0301012 | Stomach | GC | Ribosome | 64/708 | 167/8465 | 2.58e-27 | 8.26e-25 | 5.81e-25 | 64 |
hsa0517112 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
hsa0301013 | Stomach | GC | Ribosome | 64/708 | 167/8465 | 2.58e-27 | 8.26e-25 | 5.81e-25 | 64 |
hsa0517113 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
hsa0301021 | Stomach | CAG with IM | Ribosome | 63/640 | 167/8465 | 5.86e-29 | 1.86e-26 | 1.31e-26 | 63 |
hsa0517121 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
hsa0301031 | Stomach | CAG with IM | Ribosome | 63/640 | 167/8465 | 5.86e-29 | 1.86e-26 | 1.31e-26 | 63 |
hsa0517131 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS20 | SNV | Missense_Mutation | | c.40N>A | p.Glu14Lys | p.E14K | P60866 | protein_coding | tolerated(0.08) | benign(0.101) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | | c.235C>T | p.Arg79Cys | p.R79C | P60866 | protein_coding | deleterious(0.04) | benign(0.168) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RPS20 | SNV | Missense_Mutation | | c.254N>G | p.His85Arg | p.H85R | P60866 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RPS20 | SNV | Missense_Mutation | novel | c.325G>A | p.Gly109Arg | p.G109R | P60866 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | rs371598524 | c.403N>A | p.Glu135Lys | p.E135K | P60866 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.905) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RPS20 | SNV | Missense_Mutation | | c.340G>A | p.Glu114Lys | p.E114K | P60866 | protein_coding | tolerated(0.08) | benign(0.185) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RPS20 | SNV | Missense_Mutation | | c.197G>T | p.Arg66Ile | p.R66I | P60866 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RPS20 | SNV | Missense_Mutation | novel | c.304A>G | p.Thr102Ala | p.T102A | P60866 | protein_coding | deleterious(0.04) | possibly_damaging(0.852) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RPS20 | SNV | Missense_Mutation | novel | c.190N>G | p.Thr64Ala | p.T64A | P60866 | protein_coding | deleterious(0.02) | possibly_damaging(0.896) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | | c.232N>A | p.Asp78Asn | p.D78N | P60866 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |